Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Copeptin as a marker of outcome after cardiac arrest: a sub-study of the TTM trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Early hyperoxemia is associated with lower adjusted mortality after severe trauma: results from a French registry

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Assessment of pulmonary surfactant in COVID-19 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Elevated miR-9 in Cerebrospinal Fluid Is Associated with Poor Functional Outcome After Subarachnoid Hemorrhage

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Arginine vasopressin has complex actions in critically ill patients, involving vasoregulatory status, plasma volume, and cortisol levels. Copeptin, a surrogate marker for arginine vasopressin, has shown promising prognostic features in small observational studies and is used clinically for early rule out of acute coronary syndrome. The objective of this study was to explore the association between early measurements of copeptin, circulatory status, and short-term survival after out-of-hospital cardiac arrest.

METHODS: Serial blood samples were collected at 24, 48, and 72 h as part of the target temperature management at 33 °C versus 36 °C after cardiac arrest trial, an international multicenter randomized trial where unconscious survivors after out-of-hospital cardiac arrest were allocated to an intervention of 33 or 36 °C for 24 h. Primary outcome was 30-day survival with secondary endpoints circulatory cause of death and cardiovascular deterioration composite; in addition, we examined the correlation with extended the cardiovascular sequential organ failure assessment (eCvSOFA) score.

RESULTS: Six hundred ninety patients were included in the analyses, of whom 203 (30.3%) developed cardiovascular deterioration within 24 h, and 273 (39.6%) died within 30 days. Copeptin measured at 24 h was found to be independently associated with 30-day survival, hazard ratio 1.17 [1.06-1.28], p = 0.001; circulatory cause of death, odds ratio 1.03 [1.01-1.04], p = 0.001; and cardiovascular deterioration composite, odds ratio of 1.05 [1.02-1.08], p < 0.001. Copeptin at 24 h was correlated with eCvSOFA score with rho 0.19 [0.12-0.27], p < 0.001.

CONCLUSION: Copeptin is an independent marker of severity of the post cardiac arrest syndrome, partially related to circulatory failure.

TRIAL REGISTRATION: Clinical Trials, NCT01020916. Registered November 26, 2009.

Original languageEnglish
JournalCritical care (London, England)
Volume24
Issue number1
Pages (from-to)185
Number of pages1
ISSN1466-609X
DOIs
Publication statusPublished - 28 Apr 2020

    Research areas

  • Aged, Biomarkers/analysis, Female, Glycopeptides/analysis, Hospital Mortality, Humans, Male, Middle Aged, Odds Ratio, Organ Dysfunction Scores, Out-of-Hospital Cardiac Arrest/blood, Proportional Hazards Models, Statistics, Nonparametric

ID: 61746581